๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Cambridge
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Cambridge

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 2846 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 20 Sep 2026, 03:15 UTC
2846
Studies in scope
industry-sponsored, all four open statuses
1377
Recruiting now
open to new participants
539
Lead sponsors
across recruiting studies
Top sites
London 2003 Manchester 674 Birmingham 469 Glasgow 437 Cambridge 416
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca64 Merck Sharp & Dohme LLC26 Hoffmann-La Roche15 Janssen Research & Development, LLC15 AbbVie13
Site city
London2003 Manchester674 Birmingham469 Glasgow437 Cambridge416
All 426 cities
Target enrolment
to
416 of 2846 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
NCT05142189Non-Small Cell Lung Cancer
BioNTech SE
Phase 1
320
Cambridge, Cardiff, Liverpool, London, Newcastle upon Tyne
2022-06-17
Recruiting
Study of XmAbยฎ819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
NCT05433142Clear Cell Renal Cell Carcinoma
Xencor, Inc.
Phase 1
307
Cambridge
2022-06-13
Active, closed
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
NCT05367440Metastatic Prostate Cancer
AstraZeneca
Phase 1/2
174
Cambridge, Glasgow, Manchester, Plymouth
2022-06-02
Recruiting
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
NCT04879329Urothelial Carcinoma
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
372
Glasgow, Cambridge, London, Manchester, Merseyside
2022-05-03
Recruiting
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
NCT05208047Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer
Cogent Biosciences, Inc.
Phase 3
482
Cambridge, Glasgow, London, Manchester, Sheffield
2022-04-14
Active, closed
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
NCT05317416Multiple Myeloma
Pfizer
Phase 3
854
Cambridge, Birmingham, Belfast, Glasgow, Reading, Wolverhampton
2022-03-25
Active, closed
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
NCT05248646Immunoglobulin A Nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
530
Cambridge, Gloucester, Leicester, London, Salford, Swansea
2022-03-15
Active, closed
A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants โ‰ฅ16 Years of Age With Fabry Disease
NCT05206773Fabry Disease
Sanofi
Phase 3
122
Cambridge, London, Salford
2022-03-11
Active, closed
A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)
NCT05031780Sickle Cell Disease
Agios Pharmaceuticals, Inc.
Phase 2/3
286
London, Cambridge, Manchester
2022-02-11
Recruiting
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
NCT05070845Primary Immune Thrombocytopenia
Pfizer
Phase 2
91
Cambridge, Plymouth, Truro, London
2022-02-02
Active, closed
Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients
NCT05234190Rejection; Transplant, Liver, Liver Failure, Liver Diseases
Quell Therapeutics Limited
Phase 1/2
33
Birmingham, Cambridge, London
2022-01-21
Recruiting
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
NCT05102019Refractory Angina
Shockwave Medical, Inc.
Not applicable
380
Basildon, Birmingham, Bristol, Cambridge, Dorchester, Kettering, Leicester, Liverpool
2022-01-04
Active, closed
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (ฮฑ- or ฮฒ-NTDT)
NCT04770753Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
Agios Pharmaceuticals, Inc.
Phase 3
194
Cambridge, Manchester, London
2021-12-20
Active, closed
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
NCT05097287Asthma
Sanofi
Phase 4
1,339
Cambridge, Oxford, Bradford, Liverpool, Newcastle upon Tyne, Wakefield
2021-12-16
Recruiting
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
NCT05176483Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor
Exelixis
Phase 1
1,394
Cambridge, London, Middlesex
2021-12-14
Active, closed
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
NCT05116189Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms
Merck Sharp & Dohme LLC
Phase 3
643
East Sussex, Cambridge, Truro, Kendal, Dundee, Leicester, London, Cardiff
2021-12-13
Active, closed
NTLA-2002 in Adults With Hereditary Angioedema (HAE)
NCT05120830Hereditary Angioedema
Intellia Therapeutics
Phase 1/2
37
Cambridge
2021-12-10
Recruiting
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
NCT05065216Acute Stroke, Ischemic Stroke, Stroke
DiaMedica Therapeutics Inc
Phase 2/3
728
Exeter, Newcastle upon Tyne, Cambridge, London, Stoke-on-Trent, Kirkcaldy, Leeds, Middlesbrough
2021-11-07
Active, closed
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus
NCT04963296Systemic Lupus Erythematosus
Hoffmann-La Roche
Phase 3
303
Cambridge, Leeds, London, Manchester
2021-10-26
Recruiting
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
NCT04929223Metastatic Colorectal Cancer
Hoffmann-La Roche
Phase 1
542
Cambridge, Cardiff, London, Manchester, Sutton
2021-10-22
Recruiting
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
NCT05123482Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer
AstraZeneca
Phase 1/2
460
Cambridge, Cardiff, London
2021-10-18
Active, closed
A Long-term Extension Study of Ustekinumab in Pediatric Participants
NCT05092269Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 3
159
Birmingham, Cambridge, London, Sheffield, Southampton
2021-10-18
Active, closed
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT04895696Systemic Lupus Erythematosus
Beeline Medicines Corporation
Phase 2
248
Cambridge, Bradford, Manchester
2021-10-11
Recruiting
A Study of NX-1607 in Adults With Advanced Malignancies
NCT05107674Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
Nurix Therapeutics, Inc.
Phase 1
345
Sutton, Cambridge, Glasgow, London, Manchester, Newcastle, Oxford
2021-09-29
Active, closed
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
NCT04557462Primary IgA Nephropathy
Novartis Pharmaceuticals
Phase 3
448
Newcastle upon Tyne, Cambridge, Leicester, London, Salford
2021-09-20
Rows per page Showing 301–325 of 416
Previous 11 12 13 14 15 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-uk/city/cambridge

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.